SALV Salvarx Group Plc

TIDMSALV

RNS Number : 6090M

SalvaRx Group plc

31 July 2017

SalvaRx Group plc

("SalvaRx" or "the Company")

Result of AGM

SalvaRx (LON: SALV), the drug discovery and development company focused on cancer immunotherapy, is pleased to announce that at its Annual General Meeting, which was held earlier today, all resolutions were duly passed.

For more information on SalvaRx please visit: www.salvarx.io

 
SalvaRx Group plc 
Ian Walters (Chief Executive)       Tel: +1 203 441 
                                               5451 
 
Northland Capital Partners Limited  Tel: +44 (0) 20 
 Nominated Adviser and Broker             3861 6625 
Matthew Johnson / Edward Hutton 
 (Corporate Finance) 
John Howes (Corporate Broking) 
 
 
Peterhouse Corporate Finance Limited  Tel: +44 (0) 20 
 Joint Broker                               7469 0932 
 Lucy Williams / Duncan Vasey 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGRBMTTMBIJBJR

(END) Dow Jones Newswires

July 31, 2017 08:45 ET (12:45 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Dec 2024 to Jan 2025

Salvarx (LSE:SALV)
Historical Stock Chart
From Jan 2024 to Jan 2025